From artificial intelligence to developments in robotic surgery, technology continues to reshape the ASC industry in new and dynamic ways.

The latest example of this trend is Merck KGaA’s impending all-cash acquisition of SpringWorks Therapeutics, valued around ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...

Adaptive reuse became mainstream in the 1960s and ’70s, around the same time that MG founders Fred Muhlenberg and Larry ...

GBBN’s Angela Mazzi discusses new strategies on resiliency and climate change as well as a shift toward value-driven patient ...